Table 1 Characteristics of included clinical trials
Trial Characteristics; n (%) unless noted | Total (n = 333) | H1N1 (n = 261; 78%) | Ebola (n = 60; 18%) | Zika (n = 12; 4%) |
|---|---|---|---|---|
Number of participants; median (IQR) | 175 (89–445) | 200 (117–468) | 97 (53–322) | 49 (37–143) |
Fundinga | ||||
Industry | 206 (62%) | 170 (65%) | 31 (52%) | 5 (42%) |
Federal Government | 94 (28%) | 56 (22%) | 34 (57%) | 4 (33%) |
University | 89 (27%) | 62 (24%) | 23 (38%) | 4 (33%) |
Other | 35 (11%) | 24 (9%) | 11 (18%) | 0 (0%) |
Trial Phase | ||||
Phase I | 59 (18%) | 20 (8%) | 30 (50%) | 9 (75%) |
Phase IIb | 96 (29%) | 82 (31%) | 14 (23%) | 0 (0%) |
Phase IIIc | 79 (24%) | 74 (28%) | 5 (8%) | 0 (0%) |
Phase IV | 54 (16%) | 54 (21%) | 0 (0%) | 0 (0%) |
Other | 45 (14%) | 31 (12%) | 11 (18%) | 3 (25%) |
Intervention Type | ||||
Drug/biologic | 44 (13%) | 30 (11%) | 14 (23%) | 0 (0%) |
Vaccine | 276 (83%) | 225 (86%) | 42 (70%) | 9 (75%) |
Other | 13 (4%) | 6 (2%) | 4 (7%) | 3 (25%) |
Source Register | ||||
ClinicalTrials.gov | 263 (79%) | 204 (78%) | 48 (80%) | 11 (92%) |
European Union Clinical Trials Register | 32 (10%) | 32 (12%) | 0 (0%) | 0 (0%) |
Clinical Trials Registry of India | 11 (3%) | 10 (4%) | 0 (0%) | 1 (8%) |
Pan African Clinical Trials Registry | 6 (2%) | 0 (0%) | 6 (10%) | 0 (0%) |
Japan Primary Registries Network | 6 (2%) | 4 (2%) | 2 (3%) | 0 (0%) |
Other Registry | 15 (5%) | 11 (4%) | 4 (7%) | 0 (0%) |
Recruiting Status in Registry | ||||
Enrollment completed | 286 (86%) | 225 (86%) | 51 (85%) | 10 (83%) |
Enrollment not complete | 11 (3%) | 8 (3%) | 3 (5%) | 0 (0%) |
Stopped early | 16 (5%) | 14 (5%) | 2 (3%) | 0 (0%) |
Suspended/not currently enrolling | 4 (1%) | 2 (1%) | 1 (2%) | 1 (8%) |
Unknown status | 16 (5%) | 12 (5%) | 3 (5%) | 1 (8%) |